A new drug application was submitted to the FDA by Ardelyx for its drug tenapanor to control serum phosphorus in adult patients with chronic kidney disease who are on dialysis.
Ardelyx files NDA for serum phosphorus control in CKD
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.